CA-GLOBALITY
29.7.2021 14:02:13 CEST | Business Wire | Press release
Globality , the leading AI-powered digital solution for sourcing services, and Allegis Global Solutions (AGS), the leading provider of global workforce solutions, today announced a partnership that transforms services procurement management so organizations can realize the maximum value from their services spend.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005144/en/
By closing the loop between sourcing and spend management, the partnership will deliver increased value through the end-to-end procurement process, incorporating AI-powered insights every step of the way. As a result, AGS customers will benefit from real-time data and intelligence on supplier performance in Globality’s self-serve Platform, leading to better buying decisions.
“Today’s workforce is dramatically different than it was a year ago, with global enterprises more dependent than ever on external suppliers for their consulting, marketing, IT, HR, legal and other service needs for agility and adaptability,” said Globality Chief Revenue Officer Keith Hausmann. “Without the right technology, processes and information in place, businesses historically will spend 10% to 30% more on outside services. Completing the source-to-pay process with this new integration ensures AGS customers have greater insights for all their high-value services, resulting in more efficient procurement decisions, faster speed to market and better supplier quality.”
Delivering a path to improved management of services spend, the partnership provides multiple advantages:
- Faster engagement: Increasing efficiencies and accelerating speed to market by automating procurement processes with AI-powered, self-serve sourcing
- Better supplier quality: Revealing the best-performing suppliers using data-enabled intelligence to facilitate continuous machine learning
- Increased user satisfaction: Boosting adoption of the overall procurement strategy and enhancing compliance through a consumer-like, intuitive sourcing experience
- Strategic transformation: Enabling better buying decisions with more compliant supplier engagement, competitively sourced spend and greater insights into what is delivered after the contract is signed
- End-to-end value realization: Identifying optimal solutions at the best available cost and incorporating feedback that makes future sourcing activity on the Platform even more robust and intelligent
With strategic sourcing increasingly viewed as a critical source of transformational innovation for global enterprises, companies are actively seeking ways to improve their bottom line and increase efficiency gains. Globality’s Platform transforms the sourcing of high-value services by automating the demand creation, supplier identification, proposal evaluation and statement of work (SOW) creation process with an intuitive self-serve experience. Companies can dynamically source the best-fit supplier for every complex service, while AGS manages delivery, generating actionable, real-time insights and identifying opportunities for additional savings.
“From opportunity to RFP, selection, management and performance tracking, an AGS and Globality solution closes the loop on strategy and execution to deliver a continuous cycle of performance improvement and an improved end-user experience,” said AGS Head of Procurement Solutions Strategy Jon Kesman. “This end-to-end solution ensures companies only contract for what they need and no longer leave significant dollars on the table with services being poorly sourced or left unmanaged after the contract is signed.”
“The AGS and Globality solution gives users faster engagement by modernizing and simplifying what can be a cumbersome RFP process when it comes to services and ensuring better supplier quality through continuous AI-driven learning, which increases end-user satisfaction and enhances compliance in the procurement process with its easy-to-use interface,” Kesman added.
To learn more about the partnership or schedule a demo, visit https://learn.allegisglobalsolutions.com/en-us/globality .
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to revolutionize how companies buy and sell services. Through its AI-powered Platform and marketplace, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding five years ago to $310 million. For more information, visit Globality’s website at www.globality.com .
About Allegis Global Solutions
Allegis Global Solutions (AGS) is the leading provider of workforce solutions. AGS transforms the way the world acquires talent in order to deliver immediate and lasting impact. Through decades of industry experience, and with services across 60+ countries, AGS knows what it takes to innovate, consult, design and implement successful, creative and data-driven talent solutions across all workforce categories. Learn more at www.allegisglobalsolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005144/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
